4B12
Plasmodium vivax N-myristoyltransferase with a bound benzofuran inhibitor (compound 23)
Summary for 4B12
| Entry DOI | 10.2210/pdb4b12/pdb |
| Related | 4A95 4B10 4B11 4B13 4B14 |
| Descriptor | GLYCYLPEPTIDE N-TETRADECANOYLTRANSFERASE, 1-[3-methyl-4-(piperidin-4-yloxy)-1-benzofuran-2-yl]-3-phenylpropan-1-one, 2-oxopentadecyl-CoA, ... (8 entities in total) |
| Functional Keywords | transferase, plasmodium, malaria, drug design |
| Biological source | PLASMODIUM VIVAX |
| Total number of polymer chains | 3 |
| Total formula weight | 140199.28 |
| Authors | Yu, Z.,Brannigan, J.A.,Moss, D.K.,Brzozowski, A.M.,Wilkinson, A.J.,Holder, A.A.,Tate, E.W.,Leatherbarrow, R.J. (deposition date: 2012-07-06, release date: 2012-10-17, Last modification date: 2023-12-20) |
| Primary citation | Yu, Z.,Brannigan, J.A.,Moss, D.K.,Brzozowski, A.M.,Wilkinson, A.J.,Holder, A.A.,Tate, E.W.,Leatherbarrow, R.J. Design and Synthesis of Inhibitors of Plasmodium Falciparum N-Myristoyltransferase, a Promising Target for Anti-Malarial Drug Discovery. J.Med.Chem., 55:8879-, 2012 Cited by PubMed Abstract: Design of inhibitors for N-myristoyltransferase (NMT), an enzyme responsible for protein trafficking in Plasmodium falciparum , the most lethal species of parasites that cause malaria, is described. Chemistry-driven optimization of compound 1 from a focused NMT inhibitor library led to the identification of two early lead compounds 4 and 25, which showed good enzyme and cellular potency and excellent selectivity over human NMT. These molecules provide a valuable starting point for further development. PubMed: 23035716DOI: 10.1021/JM301160H PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (1.79 Å) |
Structure validation
Download full validation report
